Mª Victoria Mateos
Hospital Clínico Universitario de Salamanca · Hospital Clinico Universitario de Salamanca
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mª Victoria Mateos as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:00 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05849610 · Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple MyelomaPETHEMA Foundation · active not recruiting · High-Risk de Novo Multiple Myeloma · study chair
- Ph3NCT05558319 · NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-IberdomidePETHEMA Foundation · recruiting · Newly Diagnosed Multiple Myeloma · study chair
- Ph3NCT00480363 · QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of ProgressionPETHEMA Foundation · completed · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:00 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:00 UTC. The ranking covers the 200 most relevant of 185 PubMed records, and a shared surname and initials can bring in a namesake. All 185 on PubMed
- Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.N Engl J Med · 20081,523 citationsRCR 33.5
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.N Engl J Med · 20161,254 citationsRCR 41.8
- Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.N Engl J Med · 20151,133 citationsRCR 36.3
- Teclistamab in Relapsed or Refractory Multiple Myeloma.N Engl J Med · 20221,126 citationsRCR 79.2
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.N Engl J Med · 20151,116 citationsRCR 34.1
- 810 citationsRCR 29.6
- Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.N Engl J Med · 2023749 citationsRCR 61.8
- 715 citationsRCR 23.2
- Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.N Engl J Med · 2022670 citationsRCR 46.2
- Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.N Engl J Med · 2013452 citationsRCR 11.9